Thakre, Neha http://orcid.org/0000-0003-0837-8676
D’Cunha, Ronilda http://orcid.org/0000-0002-1317-9105
Goebel, Aline http://orcid.org/0000-0001-5059-9427
Liu, Wei http://orcid.org/0000-0003-4444-1230
Pang, Yinuo http://orcid.org/0000-0002-9731-5118
Suleiman, Ahmed A. http://orcid.org/0000-0001-8499-6316
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
https://doi.org/10.1007/s40744-022-00474-5
OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
https://doi.org/10.1136/annrheumdis-2018-eular.2140
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
https://doi.org/10.1007/s40744-022-00474-5
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
Documents that mention this clinical trial
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2
https://doi.org/10.1136/annrheumdis-2022-eular.1673
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
https://doi.org/10.1136/rmdopen-2022-002286
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2695
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
Documents that mention this clinical trial
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1
https://doi.org/10.1136/annrheumdis-2022-eular.1186
AB0559 EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2678
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
Funding for this research was provided by:
AbbVie
Article History
Received: 3 August 2022
Accepted: 14 September 2022
First Online: 30 September 2022